Jeffrey M. Besterman
- Molecular Biology top 1%
- Oncology top 2%
- Organic Chemistry top 5%
- Cell Biology top 5%
- Physiology top 10%
- Co-authors
- Pedro CuatrecasasR B LowVincent DuronioZuomei LiXiuping FuRichard M. HoffmanIntisar HusainAnna Z. Monosov
- Topics
- Histone Deacetylase Inhibitors Research (28 papers)Protein Degradation and Inhibitors (21 papers)Cancer therapeutics and mechanisms (15 papers)
- Cited by
- ToxicologyMolecular BiologyOncology
- Journals
- Proceedings of the National Academy of SciencesJournal of the American Chemical SocietyNucleic Acids Research
- Partner nations
- United StatesCanadaZimbabwe
In The Last Decade
Jeffrey M. Besterman
98 papers receiving 5.3k citations
Peers
Comparison fields: 5 of 122
- Molecular Biology 4.2k
- Oncology 1.2k
- Organic Chemistry 608
- Cell Biology 441
- Physiology 311
Countries citing papers authored by Jeffrey M. Besterman
This map shows the geographic impact of Jeffrey M. Besterman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey M. Besterman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey M. Besterman more than expected).
Fields of papers citing papers by Jeffrey M. Besterman
This network shows the impact of papers produced by Jeffrey M. Besterman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey M. Besterman. The network helps show where Jeffrey M. Besterman may publish in the future.
Co-authorship network of co-authors of Jeffrey M. Besterman
This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey M. Besterman. A scholar is included among the top collaborators of Jeffrey M. Besterman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey M. Besterman. Jeffrey M. Besterman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 23 | |
| 2 | 156 | |
| 3 | 36 | |
| 4 | 24 | |
| 5 | Induction of an anti-angiogenesis factor, Thrombospondin 1 (TSP-1), by a novel histone deacetylase inhibitor, MGCD0103, in human cancer cells in vitro and in vivo | 1 |
| 6 | In Vivo Properties of MGCD290, an Antifungal Histone Deactylase (HDAC) Inhibitor | 1 |
| 7 | 81 | |
| 8 | 73 | |
| 9 | 26 | |
| 10 | 7 | |
| 11 | 78 | |
| 12 | 21 | |
| 13 | 52 | |
| 14 | 93 | |
| 15 | 14 | |
| 16 | 26 | |
| 17 | 7 | |
| 18 | 120 | |
| 19 | 25 | |
| 20 | 21 |
About Jeffrey M. Besterman
Jeffrey M. Besterman is a scholar working on Toxicology, Cancer Research and Molecular Biology, having authored 98 papers that have together received 5.5k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (28 papers), Protein Degradation and Inhibitors (21 papers) and Cancer therapeutics and mechanisms (15 papers). The work is most often cited by research in Toxicology (266 citations), Molecular Biology (4.2k citations) and Oncology (1.2k citations). Jeffrey M. Besterman has collaborated with scholars based in United States, Canada and Zimbabwe. Frequent co-authors include Pedro Cuatrecasas, R B Low, Vincent Duronio, Zuomei Li, Xiuping Fu, Richard M. Hoffman, Intisar Husain, Anna Z. Monosov, Marielle Fournel and A. Robert MacLeod. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.